MedPath

Lysergic acid diethylamide

Generic Name
Lysergic acid diethylamide
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H25N3O
CAS Number
50-37-3
Unique Ingredient Identifier
8NA5SWF92O
Background

Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

Associated Conditions
-
Associated Therapies
-

Episode 176: Microdosing LSD & Psilocybin: The Future of Cognitive Enhancement

Microdosing psychedelics, popularized by figures like Joe Rogan and Dr. James Fadiman, involves taking small doses to enhance cognitive, emotional, or spiritual functioning without a full psychedelic experience. Despite anecdotal benefits for mental health, scientific research is limited, with studies showing mixed results on mood, creativity, and cognitive performance. Concerns include placebo effects and potential risks, highlighting the need for more research in clinical populations.
psych.ucsf.edu
·

Trip therapy: Could psychedelics become mainstream

Tom Solis, an AIDS survivor, participated in a UCSF clinical trial exploring psychedelic therapy's effects on demoralization. The trial, part of a resurgence in psychedelic research, showed promise in treating mental health disorders. Psychedelics, once stigmatized, are now being studied for their therapeutic benefits, with participants reporting lasting positive effects.

Our DNA Could Affect the Potency of Psychedelics in the Brain

A study reveals genetic variations in serotonin receptors affect psychedelic drug potency, suggesting genetics should influence clinical trials for their therapeutic use. Different gene forms of the 5-HT2A receptor showed varied responses to psychedelics, indicating genetics play a role in individual sensitivity to these drugs.

The Use of Classic Hallucinogens/Psychedelics in Mental Health Therapy

Psychedelics, acting on 5HT2A receptors, offer therapeutic potential for mental health issues, with historical and recent studies showing benefits in depression, anxiety, and addiction. Despite challenges like legal status and societal stigma, their unique mechanisms and enduring effects present healthcare policy opportunities for cost-effective, long-term treatments.

Therapeutic use of classic psychedelics to treat cancer-related psychological distress

Cancer patients often suffer psychological distress, with early research (1960s-1970s) indicating serotoninergic psychedelics (e.g., psilocybin, LSD) may help. Recent studies (2011-2016) confirm psychedelic-assisted therapy significantly improves cancer-related psychiatric and existential distress.

Psilocybin produces substantial and sustained decreases in depression and anxiety among cancer patients

A study on 51 cancer patients showed that a high dose of psilocybin significantly reduced depression and anxiety, improved quality of life, and decreased death anxiety. These effects were sustained for 6 months, with about 80% of participants showing clinically significant improvements. The mystical-type experience during the session mediated the therapeutic outcomes.
© Copyright 2025. All Rights Reserved by MedPath